{"id":562406,"date":"2025-10-20T13:00:53","date_gmt":"2025-10-20T13:00:53","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/562406\/chronic-myelomonocytic-leukemia-pipeline-2025-innovative-clinical-developments-by-20-global-leaders-delveinsight-featuring-immuneonco-biopharma-immuneonc-therapeutics-solu-therapeutics-cd4ca.html"},"modified":"2025-10-20T13:00:53","modified_gmt":"2025-10-20T13:00:53","slug":"chronic-myelomonocytic-leukemia-pipeline-2025-innovative-clinical-developments-by-20-global-leaders-delveinsight-featuring-immuneonco-biopharma-immuneonc-therapeutics-solu-therapeutics-cd4ca","status":"publish","type":"post","link":"https:\/\/www.olympiajournal.com\/news\/story\/562406\/chronic-myelomonocytic-leukemia-pipeline-2025-innovative-clinical-developments-by-20-global-leaders-delveinsight-featuring-immuneonco-biopharma-immuneonc-therapeutics-solu-therapeutics-cd4ca.html","title":{"rendered":"Chronic Myelomonocytic Leukemia Pipeline 2025: Innovative Clinical Developments by 20+ Global Leaders \u2013 DelveInsight | Featuring ImmuneOnco Biopharma, Immune-Onc Therapeutics, SOLU Therapeutics, CD4CA"},"content":{"rendered":"<div style=\"float:right;width:250px;padding:8px 10px 10px 10px\">\n<div><a rel=\"nofollow noopener\" href=\"https:\/\/www.abnewswire.com\/upload\/2025\/10\/1760599822.jpg\" style=\"border:none !important\" target=\"_blank\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chronic Myelomonocytic Leukemia Pipeline 2025: Innovative Clinical Developments by 20+ Global Leaders &ndash; DelveInsight | Featuring ImmuneOnco Biopharma, Immune-Onc Therapeutics, SOLU Therapeutics, CD4CA\" src=\"https:\/\/www.abnewswire.com\/upload\/2025\/10\/1760599822.jpg\" alt=\"Chronic Myelomonocytic Leukemia Pipeline 2025: Innovative Clinical Developments by 20+ Global Leaders &ndash; DelveInsight | Featuring ImmuneOnco Biopharma, Immune-Onc Therapeutics, SOLU Therapeutics, CD4CA\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px;border:0 solid !important\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Chronic Myelomonocytic Leukemia Pipeline 2025<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic;padding:8px 0px\">DelveInsight\u2019s, \u201cChronic Myelomonocytic Leukemia &#8211; Pipeline Insight, 2025\u201d report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify\">As Chronic Myelomonocytic Leukemia (CMML) becomes increasingly prevalent worldwide and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a rising need for safer and more effective treatments. DelveInsight reports that more than 20 pharmaceutical and biotech companies are actively developing over 25 therapeutic candidates targeting CMML. These candidates span multiple stages of clinical and preclinical development, reflecting significant innovation and commitment to addressing this critical health challenge.<\/p>\n<p style=\"text-align: justify\">The &ldquo;Chronic Myelomonocytic Leukemia Pipeline Insight 2025&rdquo; report by DelveInsight provides a comprehensive strategic overview of the current R&amp;D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives, serving as a vital resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving CMML therapeutics market and the breakthroughs shaping its future.<\/p>\n<p style=\"text-align: justify\"><strong>Explore the Cutting-Edge Landscape of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Chronic Myelomonocytic Leukemia Drug Development<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Key Takeaways from the Chronic Myelomonocytic Leukemia Pipeline Report<\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight&rsquo;s Chronic Myelomonocytic Leukemia (CMML) pipeline report highlights a dynamic landscape, with over 20 active companies developing more than 25 therapeutic candidates for CMML treatment.<\/p>\n<p style=\"text-align: justify\"><strong>Key developments in 2025 include:<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p class=\"caps\">July 2025: The oral therapy Inqovi (venetoclax for acute myeloid leukemia) is under FDA review, with a decision expected by February 25, 2026.<\/p>\n<\/li>\n<li>\n<p>July 2025: Taiho Oncology and Taiho Pharmaceutical announced the FDA&rsquo;s acceptance of a supplemental New Drug Application for INQOVI&reg; in combination with venetoclax to treat patients with acute myeloid leukemia.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Leading companies advancing CMML therapies include ImmuneOnco Biopharma, Immune-Onc Therapeutics, SOLU Therapeutics, CD4CAR, Cobimetinib, BC3402, AZD6738, APG-115, Tuspetinib, NC525, Itacitinib, LP-108, TRX103, PRT2527, DFV890, and others.<\/p>\n<p style=\"text-align: justify\">Promising pipeline candidates in various stages of development include Timdarpacept, IO-202, STX-0712, among others.<\/p>\n<p style=\"text-align: justify\"><strong>Chronic Myelomonocytic Leukemia Overview:<\/strong><\/p>\n<p style=\"text-align: justify\">Chronic myelomonocytic leukemia (CMML) is a rare blood disorder caused by the abnormal clonal expansion of hematopoietic stem cells. It is characterized by elevated monocyte counts and dysplasia (abnormal development) of myeloid precursor cells in the bone marrow. CMML falls under the category of myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN), a group that also includes atypical CML, juvenile myelomonocytic leukemia, MDS\/MPN with ring sideroblasts and thrombocytosis, and other unclassified subtypes.<\/p>\n<p style=\"text-align: justify\"><strong>Download the Chronic Myelomonocytic Leukemia sample report to know in detail about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Chronic Myelomonocytic Leukemia treatment market<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Chronic Myelomonocytic Leukemia Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>The Chronic Myelomonocytic Leukemia pipeline insights report 2025, provides insights into: <\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p>Provides comprehensive insights into key companies developing therapies in the Chronic Myelomonocytic Leukemia Market.<\/p>\n<\/li>\n<li>\n<p>Categorizes Chronic Myelomonocytic Leukemia therapeutic companies by development stage: early, mid, and late-stage.<\/p>\n<\/li>\n<li>\n<p>Highlights major companies involved in targeted therapy development, including both active and inactive (paused\/discontinued) projects.<\/p>\n<\/li>\n<li>\n<p>Reviews emerging Chronic Myelomonocytic Leukemia drugs under development based on:<\/p>\n<ul>\n<li>\n<p>Stage of development<\/p>\n<\/li>\n<li>\n<p>Chronic Myelomonocytic Leukemia Route of administration<\/p>\n<\/li>\n<li>\n<p>Target receptor<\/p>\n<\/li>\n<li>\n<p>Monotherapy vs. combination therapy<\/p>\n<\/li>\n<li>\n<p>Chronic Myelomonocytic Leukemia Mechanism of action<\/p>\n<\/li>\n<li>\n<p>Molecular type<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>Offers detailed analysis of:<\/p>\n<ul>\n<li>\n<p>Company-to-company and company-academia collaborations<\/p>\n<\/li>\n<li>\n<p>Chronic Myelomonocytic Leukemia Licensing agreements<\/p>\n<\/li>\n<li>\n<p>Funding and investment activities supporting future Chronic Myelomonocytic Leukemia market advancement.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\"><strong>Unlock key insights into emerging Chronic Myelomonocytic Leukemia therapies and market strategies here: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">https:\/\/www.delveinsight.com\/report-store\/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Chronic Myelomonocytic Leukemia Emerging Drugs<\/strong><\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>Timdarpacept: ImmuneOnco Biopharma<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">Timdarpacept is an experimental therapy in Phase III development for chronic myelomonocytic leukemia (CMML). It is a recombinant fusion protein that links Signal Regulatory Protein alpha (SIRP&alpha;) to an IgG1 backbone, designed to enhance immune system activity against cancer cells.<\/p>\n<ul style=\"text-align: justify\">\n<li>\n<p><strong>IO-202: Immune-Onc Therapeutics<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify\">IO-202 is a novel, humanized IgG1 monoclonal antibody designed to target LILRB4 (Leukocyte Immunoglobulin-Like Receptor Subfamily B4), a receptor that is highly expressed on cells linked to chronic myelomonocytic leukemia (CMML). By binding to LILRB4, IO-202 stimulates the immune system to attack cancer cells through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), promoting the destruction of malignant cells.<\/p>\n<p style=\"text-align: justify\"><strong>Chronic Myelomonocytic Leukemia Pipeline Therapeutic Assessment<\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Chronic Myelomonocytic Leukemia Assessment by Product Type<\/strong><\/p>\n<p style=\"text-align: justify\">&bull; Mono<\/p>\n<p style=\"text-align: justify\">&bull; Combination<\/p>\n<p style=\"text-align: justify\">&bull; Mono\/Combination<\/p>\n<p style=\"text-align: justify\"><strong>Chronic Myelomonocytic Leukemia By Stage<\/strong><\/p>\n<p style=\"text-align: justify\">&bull; Late-stage products (Phase III)<\/p>\n<p style=\"text-align: justify\">&bull; Mid-stage products (Phase II)<\/p>\n<p style=\"text-align: justify\">&bull; Early-stage product (Phase I) along with the details of<\/p>\n<p style=\"text-align: justify\">&bull; Pre-clinical and Discovery stage candidates<\/p>\n<p style=\"text-align: justify\">&bull; Discontinued &amp; Inactive candidates<\/p>\n<p style=\"text-align: justify\"><strong>Chronic Myelomonocytic Leukemia Assessment by Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify\">&bull; Oral<\/p>\n<p style=\"text-align: justify\">&bull; Parenteral<\/p>\n<p style=\"text-align: justify\">&bull; Intravenous<\/p>\n<p style=\"text-align: justify\">&bull; Subcutaneous<\/p>\n<p style=\"text-align: justify\">&bull; Topical<\/p>\n<p style=\"text-align: justify\"><strong>Chronic Myelomonocytic Leukemia Assessment by Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify\">&bull; Recombinant fusion proteins<\/p>\n<p style=\"text-align: justify\">&bull; Small molecule<\/p>\n<p style=\"text-align: justify\">&bull; Monoclonal antibody<\/p>\n<p style=\"text-align: justify\">&bull; Peptide<\/p>\n<p style=\"text-align: justify\">&bull; Polymer<\/p>\n<p style=\"text-align: justify\">&bull; Gene therapy<\/p>\n<p style=\"text-align: justify\"><strong>Download sample pages to get an in-depth assessment of the emerging Chronic Myelomonocytic Leukemia therapies and key <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Chronic Myelomonocytic Leukemia companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify\">1. Report Introduction<\/p>\n<p style=\"text-align: justify\">2. Executive Summary<\/p>\n<p style=\"text-align: justify\">3. Chronic Myelomonocytic Leukemia Current Treatment Patterns<\/p>\n<p style=\"text-align: justify\">4. Chronic Myelomonocytic Leukemia &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify\">6. Chronic Myelomonocytic Leukemia Late-Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify\">7. Chronic Myelomonocytic Leukemia Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify\">10. Inactive Products<\/p>\n<p style=\"text-align: justify\">11. Dormant Products<\/p>\n<p style=\"text-align: justify\">12. Chronic Myelomonocytic Leukemia Discontinued Products<\/p>\n<p style=\"text-align: justify\">13. Chronic Myelomonocytic Leukemia Product Profiles<\/p>\n<p style=\"text-align: justify\">14. Chronic Myelomonocytic Leukemia Key Companies<\/p>\n<p style=\"text-align: justify\">15. Chronic Myelomonocytic Leukemia Key Products<\/p>\n<p style=\"text-align: justify\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify\">17. Chronic Myelomonocytic Leukemia Unmet Needs<\/p>\n<p style=\"text-align: justify\">18. Chronic Myelomonocytic Leukemia Future Perspectives<\/p>\n<p style=\"text-align: justify\">19. Chronic Myelomonocytic Leukemia Analyst Review<\/p>\n<p style=\"text-align: justify\">20. Appendix<\/p>\n<p style=\"text-align: justify\">21. Report Methodology<\/p>\n<p style=\"text-align: justify\"><strong>Request the sample PDF to get detailed insights about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-myelomonocytic-leukaemia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=market&amp;utm_campaign=kpr\">Chronic Myelomonocytic Leukemia pipeline reports offerings<\/a><\/strong><\/p>\n<p style=\"text-align: justify\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a rel=\"nofollow\" href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chronic-myelomonocytic-leukemia-pipeline-2025-innovative-clinical-developments-by-20-global-leaders-delveinsight-featuring-immuneonco-biopharma-immuneonc-therapeutics-solu-therapeutics-cd4ca\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a rel=\"nofollow noopener\" href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chronic-myelomonocytic-leukemia-pipeline-2025-innovative-clinical-developments-by-20-global-leaders-delveinsight-featuring-immuneonco-biopharma-immuneonc-therapeutics-solu-therapeutics-cd4ca\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chronic Myelomonocytic Leukemia Pipeline 2025 DelveInsight\u2019s, \u201cChronic Myelomonocytic Leukemia &#8211; Pipeline Insight, 2025\u201d report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukemia pipeline landscape.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/562406"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=562406"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/562406\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=562406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=562406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=562406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}